Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy

Led by Dr.dr.Irma Bernadette, SpKK (K) · Updated on 2024-07-24

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

This research is a clinical study with a single-blind randomized clinical trial design (randomized controlled trial) in RSCM-FKUI This study aims to Assess the effectiveness and safety of intradermal concentrated secretome injection therapy, triple combination cream, and intradermal tranexamic acid injection in melasma patients, determine the quality of life profile of melasma patients after triple combination cream therapy in melasma therapy, and determine SOD levels in melasma patients. This research will be attended by 90 research subjects

CONDITIONS

Brief Title

Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy

Who Can Participate

Age: 30Years - 60Years

FEMALE

Healthy Volunteers

Eligibility Criteria

Inclusion Criteria:

Women diagnosed with melasma.
Women without melasma and have areas of skin that are clinically free of lesions for SP control.
30-60 years old.
Fitzpatrick skin type IV-V.
Willing to be a research subject by signing a research consent form (Informed Consent).

Exclusion Criteria:

Pregnant and breastfeeding women.
Currently using hormonal contraception or have ever used contraception hormones in the last 6 months.
Using topical therapy for melasma, for example corticosteroids, tretinoin, hydroquinone, and other therapies that whiten or brighten the skin in the last 2 weeks.
Using topical triple combination cream therapy for at least 3 months and did not show significant improvement
Using systemic therapy for melasma, for example antioxidants or tranexamic acid in the last 4 weeks.
History of superficial peeling therapy in the last 4 weeks.
History of deep peeling therapy, laser or mechanical abrasion in the last 6 months.
Using drugs that are photosensitizers such as tetracycline, phenytoin, carbamazepine, spironolactone.
History of blood clotting disorders or on blood thinning therapy.
Allergy to tranexamic acid.
Have other skin complaints that may interfere with the evaluation of melasma, for example post-inflammatory hyperpigmentation, Hori's nevus, Ota's nevus, pigmented contact dermatitis, and other pigmentation disorders
Difficulty complying with treatment.

Research Team

Prof. Dr. dr. Irma Bernadette S. Sitohang, SpKK(K) Sitohang

Prof. Dr. dr. Irma Bernadette S. Sitohang, SpKK(K) Sitohang Sitohang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Research Team

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria